Previous 10 | Next 10 |
home / stock / cytk / cytk articles
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced four presentations at t...
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is sch...
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 12.46% on an annualized basis producing an average annual return o...
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 5 years by 46.76% on an annualized basis producing an average annual return of...
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, Pre...
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Monday. Shares of Banco Santander, S.A. (NYSE: SAN) sh...
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 5 years by 48.59% on an annualized basis producing an average annual return of...
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced an upcoming presentation...
Thursday, Novartis AG (NYSE:NVS) decided to step back from pursuing the Cytokinetics Inc (NASDAQ:CYTK) acquisition, dealin...
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
Cytokinetics Incorporated Website:
Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and Biomarkers Analyses of Safety and Outcomes from FOREST-HCM Related to Withdrawal of Standard of Care Medications to b...
2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...